JP2016041713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016041713A5 JP2016041713A5 JP2015199079A JP2015199079A JP2016041713A5 JP 2016041713 A5 JP2016041713 A5 JP 2016041713A5 JP 2015199079 A JP2015199079 A JP 2015199079A JP 2015199079 A JP2015199079 A JP 2015199079A JP 2016041713 A5 JP2016041713 A5 JP 2016041713A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- particles
- active agent
- total mass
- metered dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002245 particle Substances 0.000 claims description 91
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims description 38
- 239000000725 suspension Substances 0.000 claims description 37
- 229960000193 formoterol fumarate Drugs 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 29
- 239000013543 active substance Substances 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 229940071648 metered dose inhaler Drugs 0.000 claims description 16
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 13
- 229960002848 formoterol Drugs 0.000 claims description 13
- 239000000375 suspending agent Substances 0.000 claims description 10
- 239000010419 fine particle Substances 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 8
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims 8
- -1 cyclopentyl-hydroxyphenylacetyl Chemical group 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 239000003380 propellant Substances 0.000 claims 4
- 230000008695 pulmonary vasoconstriction Effects 0.000 claims 4
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 2
- 206010038687 Respiratory distress Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 229940015042 glycopyrrolate Drugs 0.000 description 36
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 35
- 238000009826 distribution Methods 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000012190 activator Substances 0.000 description 11
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 8
- 229940046810 spiriva Drugs 0.000 description 8
- 230000001351 cycling effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 4
- 229940110309 tiotropium Drugs 0.000 description 4
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000004683 dihydrates Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DYDNPESBYVVLBO-UHFFFAOYSA-N formanilide Chemical compound O=CNC1=CC=CC=C1 DYDNPESBYVVLBO-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 101000894524 Bos taurus Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002943 EPDM rubber Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101000798717 Homo sapiens Transmembrane 9 superfamily member 1 Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102100032463 Transmembrane 9 superfamily member 1 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18256509P | 2009-05-29 | 2009-05-29 | |
| US61/182,565 | 2009-05-29 | ||
| US25817209P | 2009-11-04 | 2009-11-04 | |
| US61/258,172 | 2009-11-04 | ||
| US30936510P | 2010-03-01 | 2010-03-01 | |
| US61/309,365 | 2010-03-01 | ||
| US34553610P | 2010-05-17 | 2010-05-17 | |
| US61/345,536 | 2010-05-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513314A Division JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017188628A Division JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016041713A JP2016041713A (ja) | 2016-03-31 |
| JP2016041713A5 true JP2016041713A5 (enExample) | 2017-03-23 |
Family
ID=42269864
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513311A Active JP5873012B2 (ja) | 2009-05-29 | 2010-05-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2012513314A Active JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2012513319A Active JP5873013B2 (ja) | 2009-05-29 | 2010-05-28 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015199079A Withdrawn JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513311A Active JP5873012B2 (ja) | 2009-05-29 | 2010-05-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2012513314A Active JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2012513319A Active JP5873013B2 (ja) | 2009-05-29 | 2010-05-28 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Country Status (31)
| Country | Link |
|---|---|
| US (12) | US20110135737A1 (enExample) |
| EP (6) | EP2435025B1 (enExample) |
| JP (10) | JP5873012B2 (enExample) |
| KR (7) | KR101976107B1 (enExample) |
| CN (6) | CN107412212B (enExample) |
| AR (3) | AR076807A1 (enExample) |
| AU (3) | AU2010253776B2 (enExample) |
| BR (3) | BRPI1011229B8 (enExample) |
| CA (3) | CA2763941A1 (enExample) |
| CY (8) | CY1118030T1 (enExample) |
| DK (6) | DK3111927T3 (enExample) |
| ES (6) | ES2593429T3 (enExample) |
| FR (1) | FR19C1040I2 (enExample) |
| HR (6) | HRP20161098T1 (enExample) |
| HU (8) | HUE029532T2 (enExample) |
| IL (3) | IL216468B (enExample) |
| LT (8) | LT2435024T (enExample) |
| LU (2) | LUC00124I2 (enExample) |
| ME (1) | ME03631B (enExample) |
| MX (5) | MX350164B (enExample) |
| NL (1) | NL300995I2 (enExample) |
| NO (2) | NO2019026I1 (enExample) |
| PH (1) | PH12017500778A1 (enExample) |
| PL (6) | PL2435025T3 (enExample) |
| PT (6) | PT2435023T (enExample) |
| RU (5) | RU2751771C2 (enExample) |
| SI (6) | SI2435025T1 (enExample) |
| SM (6) | SMT202000109T1 (enExample) |
| TW (9) | TWI792140B (enExample) |
| WO (3) | WO2010138868A2 (enExample) |
| ZA (4) | ZA201108275B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2300568T3 (es) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | Aparato de inhalacion. |
| WO2006023849A2 (en) | 2004-08-20 | 2006-03-02 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
| KR20150039211A (ko) | 2004-08-23 | 2015-04-09 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
| US10002325B2 (en) | 2005-03-30 | 2018-06-19 | Primal Fusion Inc. | Knowledge representation systems and methods incorporating inference rules |
| WO2007033372A2 (en) | 2005-09-14 | 2007-03-22 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| SG10201507036TA (en) | 2008-06-13 | 2015-10-29 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| HUE029532T2 (en) * | 2009-05-29 | 2017-03-28 | Pearl Therapeutics Inc | Respiratory delivery of active agents |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| EP2582421A1 (en) * | 2010-06-21 | 2013-04-24 | MannKind Corporation | Dry powder drug delivery system and methods |
| US10474647B2 (en) | 2010-06-22 | 2019-11-12 | Primal Fusion Inc. | Methods and devices for customizing knowledge representation systems |
| CA3078334C (en) | 2011-04-01 | 2022-08-09 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| WO2012158166A1 (en) * | 2011-05-17 | 2012-11-22 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
| CN105106200A (zh) * | 2011-05-17 | 2015-12-02 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| GB201113662D0 (en) * | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
| CA2869849A1 (en) * | 2012-04-13 | 2013-10-17 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate |
| EP2872205B1 (en) | 2012-07-12 | 2017-02-08 | MannKind Corporation | Dry powder drug delivery systems |
| CN102872027B (zh) * | 2012-09-18 | 2014-03-12 | 刘晓忠 | 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备 |
| CA2897464C (en) * | 2013-01-28 | 2021-05-18 | Incozen Therapeutics Pvt. Ltd. | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide |
| GB201301721D0 (en) * | 2013-01-31 | 2013-03-20 | Prosonix Ltd | Pharmaceutical Preparations |
| BR112015018121A2 (pt) * | 2013-01-31 | 2017-07-18 | Prosonix Ltd | composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores |
| JP6564708B2 (ja) * | 2013-03-04 | 2019-08-21 | ベザン ヘルスケア ルクセンブルク エスエーアールエルＢｅｓｉｎｓ Ｈｅａｌｔｈｃａｒｅ Ｌｕｘｅｍｂｏｕｒｇ Ｓａｒｌ | 担体粒子に結合した活性物質ナノ粒子を含む乾燥医薬組成物 |
| JP6232079B2 (ja) * | 2013-03-14 | 2017-11-15 | ノバルティス アーゲー | スプレーブレンディングによるスプレー乾燥製剤の脱アモルファス化 |
| TR201902687T4 (tr) | 2013-03-15 | 2019-03-21 | Pearl Therapeutics Inc | İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler. |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| CA2907566C (en) | 2013-04-01 | 2023-08-22 | Pulmatrix, Inc. | Tiotropium dry powders |
| US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| HK1221654A1 (zh) * | 2013-05-22 | 2017-06-09 | 珍珠治疗公司 | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 |
| US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| MX374870B (es) * | 2013-10-07 | 2025-03-06 | Teva Branded Pharmaceutical Products R&D Inc | Inhalador de polvo seco. |
| PL2897589T3 (pl) * | 2013-11-22 | 2018-06-29 | Teva Branded Pharmaceutical Products R & D, Inc. | Lek do inhalacji |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| CN104188941B (zh) * | 2014-09-02 | 2016-11-16 | 重庆和平制药有限公司 | 一种制备盐酸克仑特罗吸入粉雾剂的方法 |
| AR102147A1 (es) * | 2014-10-01 | 2017-02-08 | Als Mountain Llc | Composición farmacéutica que comprende aspirina, metformina y serotonina con agente tensioactivo no iónico |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| WO2016170518A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| WO2017108917A1 (en) | 2015-12-22 | 2017-06-29 | Astrazeneca Ab | Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease |
| CN108883079A (zh) * | 2016-03-15 | 2018-11-23 | 广东东阳光药业有限公司 | 喷雾剂、喷雾装置以及喷雾组件 |
| EP3458156A4 (en) * | 2016-05-17 | 2019-06-05 | Mayo Foundation for Medical Education and Research | MATERIALS AND METHOD FOR TREATING CHRONIC HUSTEN |
| MX387520B (es) | 2016-06-30 | 2025-03-18 | Philip Morris Products Sa | Particulas de nicotina. |
| CN109789126B (zh) | 2016-09-19 | 2022-08-05 | 墨西哥氟石股份公司 | 药物组合物 |
| JP6906947B2 (ja) * | 2016-12-22 | 2021-07-21 | キヤノン株式会社 | 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| CN107243080B (zh) * | 2017-06-21 | 2021-11-12 | 上海上药信谊药厂有限公司 | 一种吸入式气雾剂、其原料组合物及制备方法 |
| IL302619B2 (en) * | 2017-10-09 | 2024-06-01 | Pearl Therapeutics Inc | Drug delivery systems and related methods |
| JP7372727B2 (ja) | 2017-11-20 | 2023-11-01 | 三菱重工業株式会社 | 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム |
| WO2020070620A2 (en) * | 2018-10-01 | 2020-04-09 | 3M Innovative Properties Company | Formulation and aerosol canisters, inhalers, and the like containing the formulation |
| US20210386665A1 (en) * | 2018-10-02 | 2021-12-16 | Meijo University Educational Foundation | Inhalation powder medicine, evaluation method thereof, and use thereof |
| CN109632555B (zh) * | 2018-12-28 | 2021-07-27 | 上海新黄河制药有限公司 | 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法 |
| WO2020229966A1 (en) * | 2019-05-10 | 2020-11-19 | Glenmark Pharmaceutical Limited | Stable aerosol composition for inhalation comprising glycopyrronium |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| US20200405700A1 (en) * | 2019-06-27 | 2020-12-31 | Cai Gu Huang | Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide |
| CN112972384B (zh) * | 2019-12-02 | 2022-03-18 | 长风药业股份有限公司 | 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法 |
| WO2021165348A1 (en) * | 2020-02-20 | 2021-08-26 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| AU2021276611A1 (en) * | 2020-05-18 | 2022-12-15 | Orexo Ab | New pharmaceutical composition for drug delivery |
| US20220000767A1 (en) * | 2020-07-06 | 2022-01-06 | Sensory Cloud, Inc. | Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi |
| WO2022016068A1 (en) * | 2020-07-16 | 2022-01-20 | Tbd Pharma Llc | Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections |
| CA3179014A1 (en) | 2020-09-29 | 2022-04-07 | iPharma Labs, Inc. | Liquid formulations of indacaterol |
| WO2022148418A1 (zh) * | 2021-01-08 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 可通过定量吸入器递送的药物组合物 |
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| RS65598B1 (sr) | 2021-07-09 | 2024-06-28 | Astrazeneca Pharmaceuticals Lp | Sastavi, postupci i sistemi za isporuku aerosolnog leka |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| TW202333658A (zh) | 2021-11-25 | 2023-09-01 | 瑞典商奥瑞克索股份公司 | 包含腎上腺素之新穎醫藥組合物 |
| EP4452230A1 (en) | 2021-12-20 | 2024-10-30 | Astrazeneca AB | Compositions, methods and systems for aerosol drug delivery |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| US20250345292A1 (en) | 2022-04-28 | 2025-11-13 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
| WO2024206662A1 (en) * | 2023-03-30 | 2024-10-03 | Aerorx Therapeutics Llc | Liquid formulations of indacaterol and glycopyrronium |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| US20250268914A1 (en) * | 2024-02-26 | 2025-08-28 | Honeywell International Inc. | Fluticasone delivery compositions, devices and methods |
| CN118787617A (zh) * | 2024-09-14 | 2024-10-18 | 苏州易合医药有限公司 | 一种吸入粉剂及其制备方法 |
Family Cites Families (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4187301A (en) * | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| US4335121A (en) * | 1980-02-15 | 1982-06-15 | Glaxo Group Limited | Androstane carbothioates |
| ATE8790T1 (de) * | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8432063D0 (en) | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
| US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| EP0416950B1 (en) | 1989-09-08 | 1993-08-11 | Glaxo Group Limited | Medicaments |
| US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| IE912999A1 (en) | 1990-09-07 | 1992-03-11 | Abbott Lab | Phenanthridine compounds |
| DE19875032I2 (de) | 1990-09-10 | 2007-04-19 | Schering Corp | Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen |
| DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| US5635563A (en) | 1991-04-01 | 1997-06-03 | Tomoegawa Paper Co., Ltd. | Polyaniline derivatives and their production process |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| AU659645B2 (en) * | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| SG48301A1 (en) | 1991-12-18 | 1998-04-17 | Astra Ab | New combination |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5849263A (en) | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| CA2176249C (en) | 1993-12-02 | 2010-06-01 | Akwete L. Adjei | Aerosol drug formulations for use with non-cfc propellants |
| SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| DE69502179D1 (de) * | 1994-02-09 | 1998-05-28 | Kinerton Ltd | Verfahren zur trocknung eines materials aus einer lösung |
| GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| MY131733A (en) * | 1994-12-22 | 2007-08-30 | Astra Ab | Aerosol drug formulations |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| GB9507768D0 (en) | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
| DE69634246T2 (de) * | 1995-04-14 | 2006-01-12 | Nektar Therapeutics, San Carlos | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US6309671B1 (en) * | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| DE19614421C2 (de) | 1996-04-12 | 1999-12-16 | Biovision Gmbh | Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff |
| GB9610821D0 (en) | 1996-05-23 | 1996-07-31 | Glaxo Wellcome Inc | Metering apparatus |
| US6054488A (en) * | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| GB9612297D0 (en) | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| US5886200A (en) * | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US6068832A (en) * | 1996-08-29 | 2000-05-30 | Schering Corporation | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| CN100391942C (zh) * | 1996-11-11 | 2008-06-04 | 索佛特克两合公司 | 对映异构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用 |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| EP2036544B1 (en) | 1997-03-20 | 2016-12-28 | Merck Sharp & Dohme Corp. | Dosage form of powder agglomerates |
| US6129905A (en) * | 1997-04-21 | 2000-10-10 | Aeropharm Technology, Inc. | Aerosol formulations containing a sugar as a dispersant |
| US6010935A (en) * | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| JP2003525842A (ja) | 1997-09-29 | 2003-09-02 | インヘール セラピューティック システムズ， インコーポレイテッド | 計量吸入器における使用のための安定化調製物 |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| ATE296635T1 (de) | 1998-03-05 | 2005-06-15 | Senju Pharma Co | Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| US6260549B1 (en) * | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
| US6451285B2 (en) * | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| JP4570251B2 (ja) | 1998-07-24 | 2010-10-27 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
| DE59904648D1 (de) * | 1998-08-04 | 2003-04-24 | Jago Res Ag Muttenz | Medizinische aerosolformulierungen |
| CZ303154B6 (cs) * | 1998-11-13 | 2012-05-09 | Jagotec Ag | Suchá prášková formulace k inhalaci obsahující stearát horecnatý |
| GB9912639D0 (en) * | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| JP2002532520A (ja) | 1998-12-22 | 2002-10-02 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 気道病治療および気道用薬剤送達のための化合物および方法 |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| HUP0200185A3 (en) | 1999-03-05 | 2006-07-28 | Chiesi Farma Spa | Improved powdery pharmaceutical compositions for inhalation |
| SE9900833D0 (sv) * | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US7090831B1 (en) | 1999-04-14 | 2006-08-15 | Smithkline Beecham Corporation | Pharmaceutical aerosol formulation |
| US20100197719A1 (en) * | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| DE60036214T2 (de) | 1999-06-30 | 2008-05-21 | Nektar Therapeutics, San Carlos | Verfahren und system zur herstellung von trockenem pulver mittels sprühtrocknung |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| NZ500555A (en) * | 1999-08-02 | 2000-11-24 | Hovione Int Ltd | Process for the preparation of mometasone furoate |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| TWI310688B (en) * | 1999-10-29 | 2009-06-11 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| JP2003531123A (ja) | 2000-04-13 | 2003-10-21 | イノバータ・バイオミッド・リミテッド | 医薬品 |
| US7442388B2 (en) | 2000-05-10 | 2008-10-28 | Weers Jeffry G | Phospholipid-based powders for drug delivery |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| WO2002014293A1 (en) | 2000-08-15 | 2002-02-21 | Carsten Berg | Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| US20040081627A1 (en) * | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| AU2002222118A1 (en) * | 2000-11-30 | 2002-06-11 | Vectura Limited | Pharmaceutical compositions for inhalation |
| ATE382335T1 (de) * | 2000-11-30 | 2008-01-15 | Vectura Ltd | Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation |
| GB0029562D0 (en) | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| WO2002053190A2 (en) | 2000-12-29 | 2002-07-11 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
| ITMI20010428A1 (it) * | 2001-03-02 | 2002-09-02 | Chemo Breath S A | Composizioni ad uso inalatorio a base di formoterolo |
| IL157580A0 (en) * | 2001-03-20 | 2004-03-28 | Glaxo Group Ltd | Inhalation drug combination |
| EP1372751A1 (fr) * | 2001-03-30 | 2004-01-02 | Laboratoires Genevrier | Neo-tissu cartilagineux greffable |
| PL207377B1 (pl) | 2001-03-30 | 2010-12-31 | Jagotec Ag | Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| DE10202940A1 (de) * | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
| DE10214264A1 (de) * | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen eines Anhydrats |
| GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
| KR20060011783A (ko) * | 2002-06-12 | 2006-02-03 | 에피제네시스 파마슈티칼스 아이엔씨 | 데하이드로에피안드로스테론 스테로이드 및항-무스카린제와 더불어 호흡기 및 폐 질환을 치료하기위한 조성물, 제제 및 키트 |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| CA2495689A1 (en) | 2002-08-23 | 2004-03-04 | Schering Corporation | Pharmaceutical compositions |
| CN1694689A (zh) | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| EP1551727B1 (en) * | 2002-10-15 | 2009-09-16 | Cryovac, Inc. | A process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger |
| EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| DE10323966A1 (de) | 2003-05-27 | 2004-12-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| US7862834B2 (en) | 2003-05-28 | 2011-01-04 | Novartis Pharma Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
| EP1638567B1 (en) | 2003-06-16 | 2012-02-29 | Nycomed GmbH | Composition comprising a pulmonary surfactant and sildenafil for the treatment of lung diseases |
| SE527190C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| WO2005013992A1 (en) | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
| WO2005014005A1 (en) | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation |
| SI1651270T1 (sl) | 2003-07-29 | 2007-08-31 | Boehringer Ingelheim Int | Zdravila za inhalacijo, ki obsegajo betamimetike in antiholinergik |
| WO2005013994A1 (en) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
| EP1925293A3 (en) | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| US9308199B2 (en) * | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| US7345060B2 (en) * | 2003-11-21 | 2008-03-18 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
| EP3238708A1 (en) * | 2003-12-31 | 2017-11-01 | CyDex Pharmaceuticals, Inc. | Inhalant formulation containing cyclodextrin and corticosteroid |
| HRP20080439T3 (hr) | 2004-02-06 | 2008-10-31 | Meda Pharma Gmbh & Co. Kg | Nova kombinacija antikolinergika i beta mimetika za liječenje respiratornih bolesti |
| HRP20130460T1 (hr) * | 2004-02-06 | 2013-06-30 | Meda Pharma Gmbh & Co. Kg | Kombinacija antikolinergika i glukokortikoida za dugotrajno lijeäśenje astme i kroniäśne opstruktivne bolesti pluä†a (copd) |
| US20050287077A1 (en) | 2004-02-10 | 2005-12-29 | James E. Shipley | Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| CA2570976C (en) | 2004-06-18 | 2013-08-13 | Novartis Vaccines And Diagnostics, Inc. | Methods of treatment of endobronchial infections |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| US20060140873A1 (en) | 2004-12-27 | 2006-06-29 | Chang Heng W | Aerosol pharmaceutical compositions |
| WO2006100453A1 (en) | 2005-03-24 | 2006-09-28 | Sosei R & D Ltd. | Glycopyrronium salts and their therapeutic use |
| EP2484382A1 (en) * | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
| CA2607391A1 (en) | 2005-04-23 | 2006-11-02 | Boehringer Ingelheim International Gmbh | Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| CA2609429A1 (en) | 2005-05-31 | 2006-12-07 | Boehringer Ingelheim International Gmbh | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
| EP1898894A1 (en) | 2005-06-17 | 2008-03-19 | Boehringer Ingelheim International GmbH | Mrp iv inhibitors for the treatment of respiratory diseases |
| EP1904219A4 (en) | 2005-07-15 | 2011-07-27 | Map Pharmaceuticals Inc | METHOD FOR FORMING PARTICLES |
| US20100183725A1 (en) | 2005-07-15 | 2010-07-22 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
| CN100560598C (zh) * | 2005-07-26 | 2009-11-18 | 上海奥锐特国际贸易有限公司 | 氟替卡松丙酸酯的合成方法 |
| AT502396B1 (de) | 2005-09-01 | 2007-03-15 | Montanuniv Leoben | Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| PL2098248T3 (pl) * | 2005-12-21 | 2012-11-30 | Meda Pharma Gmbh & Co Kg | Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych |
| US8263645B2 (en) * | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
| WO2007095041A2 (en) * | 2006-02-09 | 2007-08-23 | Schering Corporation | Pharmaceutical formulations |
| CA2653105A1 (en) | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0614621D0 (en) * | 2006-07-24 | 2006-08-30 | 3M Innovative Properties Co | Metered dose dispensers |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| EP2327403A3 (en) * | 2007-02-19 | 2011-08-31 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators |
| EP1964564A1 (en) * | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| EP2036572A1 (en) | 2007-09-04 | 2009-03-18 | Novo Nordisk A/S | Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle |
| CN101317821B (zh) * | 2007-11-15 | 2012-01-04 | 陈晓东 | 适用于肺部给药的超细干粉颗粒及其制备方法 |
| CN101896162B (zh) * | 2007-12-13 | 2013-06-05 | 诺瓦提斯公司 | 有机化合物 |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| FR2940162B1 (fr) | 2008-12-22 | 2011-02-25 | Boehm & Cie Ets | Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension |
| WO2010097188A1 (en) * | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
| HUE029532T2 (en) | 2009-05-29 | 2017-03-28 | Pearl Therapeutics Inc | Respiratory delivery of active agents |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| ES2675575T3 (es) | 2010-04-01 | 2018-07-11 | Chiesi Farmaceutici S.P.A. | Proceso para preparar partículas vehículo para polvos secos para inhalación |
| WO2012051426A2 (en) | 2010-10-15 | 2012-04-19 | Glaxo Group Limited | Aggregate nanoparticulate medicament formulations, manufacture and use thereof |
| MX2013009525A (es) | 2011-02-17 | 2013-10-01 | Cipla Ltd | Combinacion de glicopirrolato y un beta2-agonista. |
| JO3510B1 (ar) | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| WO2012158166A1 (en) | 2011-05-17 | 2012-11-22 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
| HK1221654A1 (zh) | 2013-05-22 | 2017-06-09 | 珍珠治疗公司 | 用於呼吸递送三种或更多种活性剂的组合物、方法和系统 |
-
2010
- 2010-05-28 HU HUE10727553A patent/HUE029532T2/en unknown
- 2010-05-28 SI SI201031262A patent/SI2435025T1/sl unknown
- 2010-05-28 PT PT107212581T patent/PT2435023T/pt unknown
- 2010-05-28 CA CA2763941A patent/CA2763941A1/en not_active Abandoned
- 2010-05-28 PT PT107275513T patent/PT2435024T/pt unknown
- 2010-05-28 MX MX2011012685A patent/MX350164B/es active IP Right Grant
- 2010-05-28 SM SM20200109T patent/SMT202000109T1/it unknown
- 2010-05-28 CN CN201610862606.5A patent/CN107412212B/zh active Active
- 2010-05-28 ES ES10727553.9T patent/ES2593429T3/es active Active
- 2010-05-28 SM SM20200077T patent/SMT202000077T1/it unknown
- 2010-05-28 MX MX2017011058A patent/MX377778B/es unknown
- 2010-05-28 KR KR1020117028583A patent/KR101976107B1/ko active Active
- 2010-05-28 ES ES10727551.3T patent/ES2589135T3/es active Active
- 2010-05-28 PT PT161648456T patent/PT3106149T/pt unknown
- 2010-05-28 DK DK16164849.8T patent/DK3111927T3/da active
- 2010-05-28 US US12/790,671 patent/US20110135737A1/en not_active Abandoned
- 2010-05-28 DK DK10727551.3T patent/DK2435024T3/en active
- 2010-05-28 DK DK10727553.9T patent/DK2435025T3/en active
- 2010-05-28 SI SI201031263A patent/SI2435023T1/sl unknown
- 2010-05-28 TW TW110100317A patent/TWI792140B/zh active
- 2010-05-28 EP EP10727553.9A patent/EP2435025B1/en active Active
- 2010-05-28 SI SI201031985T patent/SI3111926T1/sl unknown
- 2010-05-28 AU AU2010253776A patent/AU2010253776B2/en active Active
- 2010-05-28 PL PL10727553T patent/PL2435025T3/pl unknown
- 2010-05-28 SI SI201031260A patent/SI2435024T1/sl unknown
- 2010-05-28 PL PL16164845T patent/PL3106149T3/pl unknown
- 2010-05-28 JP JP2012513311A patent/JP5873012B2/ja active Active
- 2010-05-28 TW TW106115156A patent/TWI717511B/zh active
- 2010-05-28 PT PT161648449T patent/PT3111926T/pt unknown
- 2010-05-28 US US12/790,448 patent/US9463161B2/en active Active
- 2010-05-28 TW TW099117221A patent/TWI632926B/zh active
- 2010-05-28 TW TW099117219A patent/TWI546094B/zh active
- 2010-05-28 CN CN201080033310.3A patent/CN102596176B/zh active Active
- 2010-05-28 DK DK16164844.9T patent/DK3111926T3/da active
- 2010-05-28 AR ARP100101884A patent/AR076807A1/es not_active Application Discontinuation
- 2010-05-28 AR ARP100101882A patent/AR076806A1/es not_active Application Discontinuation
- 2010-05-28 HU HUE16164844A patent/HUE047803T2/hu unknown
- 2010-05-28 AR ARP100101885A patent/AR076621A1/es not_active Application Discontinuation
- 2010-05-28 LT LTEP10727551.3T patent/LT2435024T/lt unknown
- 2010-05-28 WO PCT/US2010/036659 patent/WO2010138868A2/en not_active Ceased
- 2010-05-28 HR HRP20161098TT patent/HRP20161098T1/hr unknown
- 2010-05-28 HU HUE16164849A patent/HUE047823T2/hu unknown
- 2010-05-28 ES ES16164845T patent/ES2772253T3/es active Active
- 2010-05-28 DK DK10721258.1T patent/DK2435023T3/en active
- 2010-05-28 KR KR1020177024590A patent/KR101926060B1/ko active Active
- 2010-05-28 CA CA2763939A patent/CA2763939A1/en not_active Abandoned
- 2010-05-28 LT LTEP10727553.9T patent/LT2435025T/lt unknown
- 2010-05-28 SI SI201031984T patent/SI3111927T1/sl unknown
- 2010-05-28 LT LTEP10721258.1T patent/LT2435023T/lt unknown
- 2010-05-28 EP EP16164849.8A patent/EP3111927B1/en active Active
- 2010-05-28 MX MX2011012684A patent/MX350163B/es active IP Right Grant
- 2010-05-28 ME MEP-2020-37A patent/ME03631B/me unknown
- 2010-05-28 RU RU2016107464A patent/RU2751771C2/ru active
- 2010-05-28 HR HRP20161102TT patent/HRP20161102T1/hr unknown
- 2010-05-28 TW TW107126090A patent/TWI695723B/zh active
- 2010-05-28 TW TW105111487A patent/TWI646980B/zh active
- 2010-05-28 PL PL16164849T patent/PL3111927T3/pl unknown
- 2010-05-28 PL PL16164844T patent/PL3111926T3/pl unknown
- 2010-05-28 BR BRPI1011229A patent/BRPI1011229B8/pt active IP Right Grant
- 2010-05-28 CA CA2763936A patent/CA2763936C/en active Active
- 2010-05-28 WO PCT/US2010/036650 patent/WO2010138862A2/en not_active Ceased
- 2010-05-28 HU HUE10727551A patent/HUE031229T2/en unknown
- 2010-05-28 BR BRPI1011220-0A patent/BRPI1011220B1/pt active IP Right Grant
- 2010-05-28 AU AU2010253950A patent/AU2010253950C1/en active Active
- 2010-05-28 PL PL10727551T patent/PL2435024T3/pl unknown
- 2010-05-28 HR HRP20161101TT patent/HRP20161101T1/hr unknown
- 2010-05-28 HU HUE16164845A patent/HUE047834T2/hu unknown
- 2010-05-28 JP JP2012513314A patent/JP5823383B2/ja active Active
- 2010-05-28 ES ES10721258.1T patent/ES2592536T3/es active Active
- 2010-05-28 LT LTEP16164844.9T patent/LT3111926T/lt unknown
- 2010-05-28 EP EP16164845.6A patent/EP3106149B1/en active Active
- 2010-05-28 ES ES16164849T patent/ES2774367T3/es active Active
- 2010-05-28 WO PCT/US2010/036676 patent/WO2010138884A2/en not_active Ceased
- 2010-05-28 AU AU2010253770A patent/AU2010253770B9/en active Active
- 2010-05-28 KR KR1020197012625A patent/KR20190049943A/ko not_active Ceased
- 2010-05-28 TW TW107143778A patent/TWI707700B/zh active
- 2010-05-28 BR BRPI1011508A patent/BRPI1011508A2/pt not_active Application Discontinuation
- 2010-05-28 SM SM20200108T patent/SMT202000108T1/it unknown
- 2010-05-28 PL PL10721258T patent/PL2435023T3/pl unknown
- 2010-05-28 CN CN201710722981.4A patent/CN107669664B/zh active Active
- 2010-05-28 JP JP2012513319A patent/JP5873013B2/ja active Active
- 2010-05-28 US US12/790,605 patent/US8808713B2/en active Active
- 2010-05-28 RU RU2011154083A patent/RU2580315C3/ru active Protection Beyond IP Right Term
- 2010-05-28 PT PT107275539T patent/PT2435025T/pt unknown
- 2010-05-28 HU HUE10721258A patent/HUE031283T2/hu unknown
- 2010-05-28 CN CN201080033312.2A patent/CN102753152B/zh active Active
- 2010-05-28 TW TW105116641A patent/TWI633898B/zh active
- 2010-05-28 EP EP10727551.3A patent/EP2435024B1/en active Active
- 2010-05-28 CN CN201510450391.1A patent/CN105193773B/zh active Active
- 2010-05-28 KR KR1020187034755A patent/KR20180130602A/ko not_active Abandoned
- 2010-05-28 KR KR1020117028582A patent/KR20120015334A/ko not_active Ceased
- 2010-05-28 EP EP16164844.9A patent/EP3111926B1/en active Active
- 2010-05-28 MX MX2020004077A patent/MX393243B/es unknown
- 2010-05-28 US US12/790,710 patent/US20110132357A1/en not_active Abandoned
- 2010-05-28 MX MX2011012783A patent/MX337126B/es active IP Right Grant
- 2010-05-28 LT LTEP16164845.6T patent/LT3106149T/lt unknown
- 2010-05-28 TW TW099117220A patent/TWI539979B/zh active
- 2010-05-28 KR KR1020117028551A patent/KR101748892B1/ko active Active
- 2010-05-28 RU RU2016117972A patent/RU2016117972A/ru not_active Application Discontinuation
- 2010-05-28 KR KR1020177016074A patent/KR20170070274A/ko not_active Ceased
- 2010-05-28 DK DK16164845.6T patent/DK3106149T3/da active
- 2010-05-28 SI SI201031975T patent/SI3106149T1/sl unknown
- 2010-05-28 ES ES16164844T patent/ES2774391T3/es active Active
- 2010-05-28 EP EP10721258.1A patent/EP2435023B1/en active Active
- 2010-05-28 CN CN201080033311.8A patent/CN102458364B/zh active Active
- 2010-05-28 PT PT161648498T patent/PT3111927T/pt unknown
- 2010-05-28 LT LTEP16164849.8T patent/LT3111927T/lt unknown
- 2010-05-28 RU RU2015151358A patent/RU2713404C2/ru active
-
2011
- 2011-11-10 ZA ZA2011/08275A patent/ZA201108275B/en unknown
- 2011-11-20 IL IL216468A patent/IL216468B/en active IP Right Grant
- 2011-11-20 IL IL216466A patent/IL216466B/en active IP Right Grant
- 2011-11-20 IL IL216467A patent/IL216467B/en active IP Right Grant
-
2012
- 2012-10-26 ZA ZA2012/08101A patent/ZA201208101B/en unknown
- 2012-10-26 ZA ZA2012/08100A patent/ZA201208100B/en unknown
- 2012-10-26 ZA ZA2012/08102A patent/ZA201208102B/en unknown
-
2014
- 2014-07-09 US US14/327,425 patent/US20150017247A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084240A patent/JP6189356B2/ja active Active
- 2015-04-16 JP JP2015084226A patent/JP6169639B2/ja active Active
- 2015-10-07 JP JP2015199079A patent/JP2016041713A/ja not_active Withdrawn
-
2016
- 2016-04-21 US US15/135,389 patent/US20170071850A1/en not_active Abandoned
- 2016-08-30 US US15/252,001 patent/US20170112759A1/en not_active Abandoned
- 2016-09-20 SM SM201600327T patent/SMT201600327B/it unknown
- 2016-09-20 SM SM201600326T patent/SMT201600326B/it unknown
- 2016-09-21 CY CY20161100941T patent/CY1118030T1/el unknown
- 2016-09-21 SM SM201600329T patent/SMT201600329B/it unknown
- 2016-09-21 CY CY20161100940T patent/CY1118034T1/el unknown
- 2016-09-21 CY CY20161100939T patent/CY1118040T1/el unknown
-
2017
- 2017-04-26 PH PH12017500778A patent/PH12017500778A1/en unknown
- 2017-06-15 US US15/624,597 patent/US20180125776A1/en not_active Abandoned
- 2017-06-28 JP JP2017125969A patent/JP6492124B2/ja active Active
- 2017-08-02 JP JP2017149555A patent/JP6348645B2/ja active Active
- 2017-09-28 JP JP2017188628A patent/JP2018048150A/ja active Pending
-
2018
- 2018-02-16 US US15/932,249 patent/US20190038548A1/en not_active Abandoned
- 2018-11-02 US US16/179,712 patent/US10716753B2/en active Active
-
2019
- 2019-03-04 JP JP2019038501A patent/JP6876734B2/ja active Active
- 2019-06-06 CY CY2019031C patent/CY2019031I2/el unknown
- 2019-06-12 FR FR19C1040C patent/FR19C1040I2/fr active Active
- 2019-06-12 HU HUS1900031C patent/HUS1900031I1/hu unknown
- 2019-06-12 LU LU00124C patent/LUC00124I2/fr unknown
- 2019-06-13 NO NO2019026C patent/NO2019026I1/no unknown
- 2019-06-14 NL NL300995C patent/NL300995I2/nl unknown
- 2019-06-17 LT LTPA2019014C patent/LTC2435025I2/lt unknown
-
2020
- 2020-01-24 RU RU2020102859A patent/RU2020102859A/ru unknown
- 2020-01-31 HR HRP20200166TT patent/HRP20200166T1/hr unknown
- 2020-02-14 CY CY20201100136T patent/CY1122749T1/el unknown
- 2020-02-17 HR HRP20200260TT patent/HRP20200260T1/hr unknown
- 2020-02-21 HR HRP20200298TT patent/HRP20200298T1/hr unknown
- 2020-02-25 CY CY20201100173T patent/CY1122732T1/el unknown
- 2020-02-28 CY CY20201100185T patent/CY1122807T1/el unknown
- 2020-08-03 US US16/983,543 patent/US20210186861A1/en not_active Abandoned
-
2021
- 2021-05-10 CY CY2021012C patent/CY2021012I2/el unknown
- 2021-05-12 NO NO2021019C patent/NO2021019I1/no unknown
- 2021-05-12 HU HUS2100018C patent/HUS2100018I1/hu unknown
- 2021-05-19 LU LU00208C patent/LUC00208I2/fr unknown
- 2021-06-04 LT LTPA2021511C patent/LTC2435024I2/lt unknown
-
2024
- 2024-02-20 US US18/582,344 patent/US20250009652A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016041713A5 (enExample) | ||
| US20250009652A1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| US20190358150A1 (en) | Compositions, methods & systems for respiratory delivery of two or more active agents | |
| JP2012528200A5 (enExample) | ||
| US20150150787A1 (en) | Compositions, methods & systems for respiratory delivery of three or more active agents | |
| AU2011368334A1 (en) | Compositions, methods & systems for respiratory delivery of two or more active agents | |
| EP4514358A1 (en) | Combination of albuterol and budesonide for the treatment of asthma | |
| AU2018282272B2 (en) | Compositions, methods & systems for respiratory delivery of two or more active agents | |
| AU2019203814A1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| AU2015201864A1 (en) | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems | |
| HK1228797A (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| HK1228797A1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems |